Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Annette S Gross"'
Autor:
Chaoying Hu, Debra Tompson, Mindy Magee, Qian Chen, Yan Mei Liu, Wenjing Zhu, Hongxin Zhao, Annette S Gross, Yun Liu
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0139862 (2015)
Darapladib is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. This study evaluated the pharmacokinetics, pharmacodynamics and safety of darapladib in healthy Chinese subjects.Twenty-four subjects received darapladib 160 mg orally, appr
Externí odkaz:
https://doaj.org/article/3fc59d80f5a14f8ab4757670f3edee5a
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 4, Pp n/a-n/a (2023)
Abstract We aimed to use physiologically based pharmacokinetic (PBPK) modeling and simulation to predict imatinib steady‐state plasma exposure in patients with chronic myeloid leukemia (CML) to investigate variability in outcomes. A validated imati
Externí odkaz:
https://doaj.org/article/639c704b3e3a43ecaec0d443cd48baa2
Publikováno v:
Haematologica, Vol 108, Iss 8 (2023)
Externí odkaz:
https://doaj.org/article/438d0dd4a3f1488cb83e8ab301404437
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 5, Pp n/a-n/a (2022)
Abstract Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of chronic myeloid leukemia (CML), but patients still experience treatment‐limiting toxicities or therapeutic failure. To investigate the real‐world use and outcomes of i
Externí odkaz:
https://doaj.org/article/a1cea837c9394e8382e02204fb8a0205
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 2, Pp n/a-n/a (2022)
ABSTRACT Treatment response to clopidogrel is associated with CYP2C19 activity through the formation of the active H4 metabolite. The aims of this study were to develop a physiologically based pharmacokinetic (PBPK) model of clopidogrel and its metab
Externí odkaz:
https://doaj.org/article/76886a6fd99141f4a2e9d02a0f88606b
Autor:
Jorge E. B. da Rocha, Houcemeddine Othman, Gerrit Botha, Laura Cottino, David Twesigomwe, Samah Ahmed, Britt I. Drögemöller, Faisal M. Fadlelmola, Philip Machanick, Mamana Mbiyavanga, Sumir Panji, Galen E. B. Wright, Clement Adebamowo, Mogomotsi Matshaba, Michéle Ramsay, Gustave Simo, Martin C. Simuunza, Caroline T. Tiemessen, Sandra Baldwin, Mathias Chiano, Charles Cox, Annette S. Gross, Pamela Thomas, Francisco-Javier Gamo, Scott Hazelhurst
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Introduction: Investigating variation in genes involved in the absorption, distribution, metabolism, and excretion (ADME) of drugs are key to characterizing pharmacogenomic (PGx) relationships. ADME gene variation is relatively well characterized in
Externí odkaz:
https://doaj.org/article/99ceb47f7191413f978d2697836a9538
Autor:
Aline, Barth, Mohammad, Hossain, Caroline R, Perry, Annette S, Gross, Hirofumi, Ogura, Shaila, Shabbir, Sebin, Thomas, Etienne F, Dumont, Darin B, Brimhall, Meenakshi, Srinivasan, Brandon, Swift
Publikováno v:
Clinical Pharmacology in Drug Development. 12:38-56
Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic in late-phase development for uncomplicated urinary tract infection and uncomplicated urogenital gonorrhea. Two clinical studies were conducted to assess the pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5f90dd10aea61844bbd15372861dd8e
https://doi.org/10.1002/cpdd.1192
https://doi.org/10.1002/cpdd.1192
Publikováno v:
British Journal of Clinical Pharmacology. 88:2700-2717
Although the number of countries participating in pivotal trials submitted to enable drug registration has nearly doubled over the past 25 years, there has not been a substantial increase in the diversity of clinical trial populations. In parallel, o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e52a970aad33e5c149e2db03a2c21b4b
https://doi.org/10.1111/bcp.15242
https://doi.org/10.1111/bcp.15242
Autor:
Lia Liefaard, Eva Hajduk, Frans van den Berg, Eirini Panoilia, Gerben Bouma, Edoardo Lisi, Naren Srinivasan, Yi Cui, Annette S. Gross, Ruth Tarzi, Daniel J.B. Marks
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(11)
This study investigated ethnic differences in the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2831781, an anti-lymphocyte activation gene 3 (LAG3) monoclonal antibody, in healthy participants, and determined local tolerability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a826d6fb26d6f863bac99ea3d4e5b42f
https://pubmed.ncbi.nlm.nih.gov/36088650
https://pubmed.ncbi.nlm.nih.gov/36088650
Autor:
Ryutaro Shimamura, Debra J. Tompson, Annette S. Gross, Hirofumi Ogura, Takashi Nagakubo, Nicola Scott, Edward P. Cannons, Hiroko Ino, Atsushi Nakano, Michalis Kostapanos, Carwyn Davies, Marcy Powell, Harue Igarashi
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Funder: GlaxoSmithKline; doi: http://dx.doi.org/10.13039/100004330
BACKGROUND AND OBJECTIVES: GSK2982772 is an oral small-molecule RIPK1 inhibitor with potential therapeutic efficacy in immune-mediated inflammatory diseases (IMIDs). An inter-eth
BACKGROUND AND OBJECTIVES: GSK2982772 is an oral small-molecule RIPK1 inhibitor with potential therapeutic efficacy in immune-mediated inflammatory diseases (IMIDs). An inter-eth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f41545899729ab6dd03f18011ef0bbaa
http://europepmc.org/articles/PMC7811991
http://europepmc.org/articles/PMC7811991